三迭纪达成一项新战略合作并获股权投资，将加速推进口服药物开发｜道彤Family

背景

Background

2026年10月9日，**道彤Family企业——三迭纪（南京）医药科技股份有限公司（**以下简称“三迭纪”或“公司”）宣布，*公司及其全资子公司三迭纪（上海）医药科技有限公司已与强生（Johnson & Johnson）签署合作与许可协议。双方将结合强生在药物开发方面的专业积累，以及三迭纪在3D打印制药和多肽等药物口服递送方面的技术能力，联合开发新型口服药物。强生旗下风险投资机构强生创投（JJDC）同步对三迭纪进行股权投资。

三迭纪将依托熔融挤出沉积联合半固体挤出（MED&SSE）的3D打印制药技术及3DμS®-OM平台，将室温、低剪切制造工艺与药片结构及药物释放特征设计相结合，以解决口服药物开发中的递送难题。

成森平博士

三迭纪创始人兼CEO成森平博士表示：我们非常荣幸与强生达成战略合作，并获得JJDC的股权投资，这充分体现了双方致力于推动口服药物研发的共同愿景。我们期待通过双方合作，加速下一代创新口服药物的开发，为患者带来更多具有临床价值的治疗选择。

*本次合作与许可协议由Janssen Pharmaceutica NV作为强生方面的法律签约主体签署。

Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines

NANJING, China, October 9, 2026 — Triastek, Inc. ("Triastek" or the "Company") announced that the Company and its wholly owned subsidiary, Triastek (Shanghai) Limited, have entered into a Collaboration and License Agreement with Johnson & Johnson*. The collaboration aims to combine Johnson & Johnson's expertise in drug development with Triastek's 3D printing pharmaceutical technology and oral drug delivery capabilities for peptides and other therapeutic modalities to develop novel oral medicines. Johnson & Johnson will also make an equity investment in Triastek through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.

Triastek will leverage its MED&SSE (Melt Extrusion Deposition plus Semi-Solid Extrusion) 3D printing pharmaceutical technology and 3D Microstructure for Oral Macromolecules (3DμS®-OM) platform, combining room-temperature, low-shear manufacturing processes with the design of tablet structures and drug release profiles to address oral delivery challenges.

Dr. Senping Cheng, Founder and CEO of Triastek, said: "We greatly value the opportunity to collaborate with Johnson & Johnson. The collaboration, together with JJDC's investment, reflects a shared commitment to advancing the development of oral medicines. We look forward to working together to accelerate the development of next-generation oral medicines and ultimately translate innovation into clinical value for patients."

*Legal entity: Janssen Pharmaceutica NV

END

ID：daltonventure

长按关注

推 荐 阅 读